INMB Nasdaq 2024: XPro and INKmune Platforms

INMB presents two clinical platforms targeting CNS and oncology. XPro treats Alzheimer's as an immunologic disease without immunosuppression, while INKmune creates memory-like NK cells for solid tumors. Phase 2 Alzheimer's data expected early 2025 and Phase 1 metastatic prostate cancer results anticipated late 2024.